Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CNCE

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Benzinga · May 23, 2022

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga · May 13, 2022

Concert Pharma: Q1 Earnings Insights

Concert Pharma (NASDAQ:CNCE) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 5, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Outlook For Concert Pharmaceuticals

Concert Pharmaceuticals (NASDAQ:CNCE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Concert Pharmaceuticals will report an earnings per share (EPS) of $-0.91.

Benzinga · May 4, 2022

Concert Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Concert Pharmaceuticals (NASDAQ:CNCE) reported Q4 sales of $13.00 thousand. Earnings fell to a loss of $36.13 million, resulting in a 35.43% decrease from last quarter.

Benzinga · Mar 8, 2022

Recap: Concert Pharmaceuticals Q4 Earnings

Concert Pharmaceuticals (NASDAQ:CNCE) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 3, 2022

A Preview Of Concert Pharmaceuticals's Earnings

Concert Pharmaceuticals (NASDAQ:CNCE) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Concert Pharmaceuticals will report an earnings per share (EPS) of $-0.73.

Benzinga · Mar 2, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

alopecia

138 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.